SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?

Dario Pitocco, Linda Tartaglione, Luca Viti, Mauro Di Leo, Alfredo Pontecorvi, Salvatore Caputo

Research output: Contribution to journalComment/debatepeer-review


Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn't represent a plausible approach to mitigate COVID-19.

Original languageEnglish
Article number108162
JournalDiabetes Research and Clinical Practice
Publication statusPublished - May 2020


  • ACE 2
  • COVID 19
  • Diabetes
  • DPP4

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?'. Together they form a unique fingerprint.

Cite this